Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

biocrea expands management team

This article was originally published in Scrip

Executive Summary

German CNS therapeutics company, biocrea GmbH, a management buy-out from Finland's Biotie Therapies, has expanded its management team by appointing Dr Martin Gunthorpe as Chief Scientific Officer, Mr Viktor Viehweg to the position of Chief Financial Officer, and Professor Simon Ward to Executive Vice President Chemistry & Development. Dr Gunthorpe joins biocrea from GlaxoSmithKline, where he was Head of Electrophysiology and Project Leader in the Neurosciences Centre of Excellence for Drug Discovery. Professor Ward also joins biocrea from GSK, where he has been Assistant Director and a member of business unit & chemistry leadership teams, he also holds the Chair of Medicinal Chemistry at the University of Sussex, UK. Mr Viehweg was most recently Head of Corporate Strategy at Moscow-based Sibur Ltd.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC011152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel